Pharsight

Drugs that contain Nusinersen Sodium

1. Spinraza patents expiration

SPINRAZA's oppositions filed in EPO
Can you believe SPINRAZA received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6166197 BIOGEN IDEC Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
Dec, 2017

(6 years ago)

US7101993 BIOGEN IDEC Oligonucleotides containing 2′-O-modified purines
Sep, 2023

(8 months ago)

US7838657 BIOGEN IDEC Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences
Jul, 2027

(3 years from now)

US8361977 BIOGEN IDEC Compositions and methods for modulation of SMN2 splicing
Dec, 2030

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6210892 BIOGEN IDEC Alteration of cellular behavior by antisense modulation of mRNA processing
Oct, 2018

(5 years ago)

US10266822 BIOGEN IDEC Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences
Dec, 2025

(1 year, 6 months from now)

US8110560 BIOGEN IDEC Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences
Dec, 2025

(1 year, 6 months from now)

US9717750 BIOGEN IDEC Compositions and methods for modulation of SMN2 splicing in a subject
Jun, 2030

(6 years from now)

US8980853 BIOGEN IDEC Compositions and methods for modulation of SMN2 splicing in a subject
Nov, 2030

(6 years from now)

US9926559 BIOGEN IDEC Compositions and methods for modulation of SMN2 splicing in a subject
Jan, 2034

(9 years from now)

US10436802 BIOGEN IDEC Methods for treating spinal muscular atrophy
Sep, 2035

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-226) May 14, 2021
Orphan Drug Exclusivity(ODE-127) Dec 23, 2023
New Chemical Entity Exclusivity(NCE) Dec 23, 2021
Orphan Drug Exclusivity(ODE) Dec 23, 2023

NCE-1 date: 23 December, 2020

Market Authorisation Date: 23 December, 2016

Treatment: Treatment of spinal muscular atrophy by increasing exon-7 inclusion in smn2 mrna; Treatment of spinal muscular atrophy; Treatment of infantile-onset spinal muscular atrophy

Dosage: SOLUTION;INTRATHECAL

More Information on Dosage

SPINRAZA family patents

Family Patents